Hospital Infantil de Mexico Federico Gomez

Mexico City, Mexico City 6720

1 studies enrolling now · 7 studies all time

What they study most

Active Nonsegmental Vitiligo, Atopic Dermatitis, COVID-19, Eczema, Human Immunodeficiency Virus, Muscular Atrophy, Spinal, Stable Nonsegmental Vitiligo, Vitiligo

Studies at this site

• EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease — Recruiting now
• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Enrolling by invitation
• A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo — Running, not enrolling
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo — Completed
• A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) — Running, not enrolling
• Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy — Completed
• An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children — Status unconfirmed